Summary of patients participating in the study
| Diagnosis . | Patient no. . | Therapy protocol* . | Maximal Cyt c level (d)† . | Maximal LDH level (d)† . |
|---|---|---|---|---|
| AML | 1, 3, 6, 11 | TAD (thioguanine, cytosine arabinoside, daunorubicin)28 | 3, 4, 2, 2 | 0, 5, 0, 4 |
| 2 | HAM (high-dose cytosine arabinoside, mitoxantrone)29 | 3 | 0 | |
| 14 | Cytosine arabinoside‡ | 2 | 0 | |
| 9 | Cytosine arabinoside, daunorubicin—remission support281-153 | 1 | 0 | |
| ALL | 13 | GMALL (for elderly patient)1-155,1-154 | 3 | 1 |
| NHL | 10 | DexaBEAM (dexamethasone, carmustine, melphalan, cytosine arabinoside, etoposide)30 | 2 | 0 |
| 4, 17 | CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone) + anti-CD2031 32 | 2, 4 | 0, 0 | |
| 12, 16 | CHOP (cyclophosphamide, vincristine, prednisolone, doxorubicin)33 | 2, 1 | 4, 0 | |
| 5 | ICE (ifosfamide, carboplatin, etoposide)34 | 2 | 0 | |
| Morbus Hodgkin | 7 | DHAP (dexamethasone, high-dose cytosine arabinoside, cisplatin)351-159 | 4 | 3 |
| NSCLC | 15 | Cisplatin, etoposide | 1 | 0 |
| Breast cancer | 8 | Epirubicin, paclitaxel36 | 2 | 1 |
| Diagnosis . | Patient no. . | Therapy protocol* . | Maximal Cyt c level (d)† . | Maximal LDH level (d)† . |
|---|---|---|---|---|
| AML | 1, 3, 6, 11 | TAD (thioguanine, cytosine arabinoside, daunorubicin)28 | 3, 4, 2, 2 | 0, 5, 0, 4 |
| 2 | HAM (high-dose cytosine arabinoside, mitoxantrone)29 | 3 | 0 | |
| 14 | Cytosine arabinoside‡ | 2 | 0 | |
| 9 | Cytosine arabinoside, daunorubicin—remission support281-153 | 1 | 0 | |
| ALL | 13 | GMALL (for elderly patient)1-155,1-154 | 3 | 1 |
| NHL | 10 | DexaBEAM (dexamethasone, carmustine, melphalan, cytosine arabinoside, etoposide)30 | 2 | 0 |
| 4, 17 | CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone) + anti-CD2031 32 | 2, 4 | 0, 0 | |
| 12, 16 | CHOP (cyclophosphamide, vincristine, prednisolone, doxorubicin)33 | 2, 1 | 4, 0 | |
| 5 | ICE (ifosfamide, carboplatin, etoposide)34 | 2 | 0 | |
| Morbus Hodgkin | 7 | DHAP (dexamethasone, high-dose cytosine arabinoside, cisplatin)351-159 | 4 | 3 |
| NSCLC | 15 | Cisplatin, etoposide | 1 | 0 |
| Breast cancer | 8 | Epirubicin, paclitaxel36 | 2 | 1 |
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; NSCLC, non–small-cell lung cancer.
Detailed information can be obtained from authors W.E.B. and M.K.
Day 0 indicates that maximal cytochrome c or LDH levels were detected before the onset of chemotherapy.
Day 1-7: cytosine arabinoside.
Day 1-25: prednisolone; day 1: vincristine; day 5, 12, 19, 26: vincristine, daunorubicin; day 5-31: L-asparaginase (every second day).
German Multicenter ALL study.
Day 1-5, day 11-14: dexamethasone; day 1-3: cyclophosphamide; day 4, 11: vincristine; day 4, 7, 11, 14: idarubicin; (intradural therapy, day 1, 10, 18: methotrexate; day 10, 18: dexamethasone, cytosine arabinoside).
With modifications.